90% of people given vaccine by Sinovac show promising results

90%接种了北京科兴公司疫苗的人收到了令人满意的效果

Beijing Sinovac Biotech Ltd said its coronavirus shot is safe and capable of eliciting an immune response from human trials, suggesting the shot's potential in defending against infection of the coronavirus disease.

北京科兴生物公司日前宣称：其研制的新型冠状病毒制剂是安全的，并且能够在人体试验中激发人体的免疫反应，这表明该制剂有机会用于防治新冠肺炎疾病。

The Beijing-based company's vaccine, called CoronaVac, hasn't caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralising antibodies two weeks after inoculation, Sinovac said in a press release on Sunday.

科兴公司上周日称：这个疫苗命名为“冠状疫苗”，目前还没有明显的副作用，并且90%的人在接种间隔为14天的情况下，在两周之后产生了中和抗体。

The preliminary findings come from phase I and II trials in China. A total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will be uncovered from another group in the trial that received shots on a 28-day interval. Sinovac plans to publish its results in academic journals, according to a company spokesperson.

公司的一名发言人称：之前的结论来自于一期和二期试验，743名年龄在18岁到59岁志愿者们分两次被注射了疫苗或是安慰剂。等到另一组接种间隔为28天的试验结束之后，我们将得到更多数据，并计划到时候发表在医学杂志上。

Using a killed version of the coronavirus, Sinovac's vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use. 

科兴公司研制的该疫苗是基于死亡的新冠病毒，目前已经到达了大规模生产前的关键性人体试验阶段，目前在中国国内达到此阶段的疫苗共有五个。

The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a pandemic that so far infected more than 7.7 million people.

该公司已经宣布与布坦坦研究所（Instituto Butantan）合作，并在巴西共同进行第三阶段试验，巴西也是第二严重的疫区，目前，感染新冠病毒的总人数达770万人。

Since lockdowns and social-distancing measures have helped to keep infection rates low in many countries, some of the world's leading vaccine efforts are seeking to conduct phase III trial in active outbreaks to evaluate the effectiveness of their shots.

鉴于封禁和保持社交距离等措施帮助一些国家成功地保持了较低的感染率，所以一些世界顶尖的疫苗研究都在寻求在感染较为严重的地区来进行疫苗的第三期试验，以此来评估疫苗的有效性。

Authorities in Brazil have approved the vaccine co-developed by the University of Oxford and AstraZeneca Plc to carry out late stage trials there, while Cambridge, Massachusetts-based Moderna Inc is set to go into phase III trials in the US.

巴西还同意了由牛津大学（University of Oxford）和阿斯利康制药公司（AstraZeneca Plc）合作开发的疫苗在巴西进行后期试验。与此同时，剑桥大学（Cambridge）和马萨诸塞州的摩登那公司（Moderna Inc）也将在美国进行疫苗的三期试验。

外文链接：https://www.msn.com/en-ae/news/coronavirus/90percent-of-people-given-vaccine-by-sinovac-show-promising-results/ar-BB15tZoX?li=BBqrVLO&ocid=mailsignout